The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China.
Theranostics. 2018 Jul 30;8(15):4238-4246. doi: 10.7150/thno.24387. eCollection 2018.
Cancer vaccines have encountered their ideal personalized partner along with evidence for great breakthroughs in the identification and synthesis of neoantigens. Individual cancer neoantigen vaccines are capable of eliciting robust T-cell responses and have been demonstrated to achieve striking clinical efficacy due to their high immunogenicity and central thymic tolerance escape of neoantigens. Two recent phase I clinical trials have provided support for the hypothesis and have heralded a nascent era of personalized vaccines in the field of immunotherapy. This review aims to address the identification of neoepitopes and describes advances made in personalized vaccines. In addition, this review discusses the challenges related to the exploitation of vaccine therapy, and provides potential thoughts for the improvement of vaccine design and applications.
癌症疫苗遇到了理想的个性化伙伴，同时在鉴定和合成新抗原方面也取得了重大突破的证据。由于新抗原的高免疫原性和中央胸腺耐受逃逸，个体癌症新抗原疫苗能够引发强大的 T 细胞反应，并已被证明具有显著的临床疗效。最近的两项 I 期临床试验为这一假说提供了支持，并开创了免疫治疗领域个性化疫苗的崭新时代。本文旨在探讨新表位的鉴定，并描述个性化疫苗的进展。此外，本文还讨论了疫苗治疗相关的挑战，并为改进疫苗设计和应用提供了潜在的思路。
